Results 11 to 20 of about 79,407 (254)

Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real‐world insights from BICSTaR cohorts

HIV Medicine, 2023
Real‐world evidence is an essential component of evidence‐based medicine. The aim of the BICSTaR (BICtegravir Single Tablet Regimen) study is to assess effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ...
Stefan Esser, J. Brunetta, A. Inciarte, Itzchak Levy, Antonella d’Arminio Monforte, John S Lambert, B. V. van Welzen, Katsuji Teruya, M. Boffito, Chun-Eng Liu, Ozlem Altuntas Aydin, D. Thorpe, Marion Heinzkill, A. Marongiu, Tali Cassidy, R. Haubrich, Lisa D'Amato, Olivier Robineau   +17 more
semanticscholar   +1 more source

Use of Tenofovir Alafenamide Fumarate for HIV Pre-Exposure Prophylaxis and Incidence of Hypertension and Initiation of Statins

JAMA Network Open, 2023
This cohort study examines the risk of incident hypertension and statin initiation among adults starting pre-exposure prophylaxis with tenofovir alafenamide fumarate compared with propensity score–matched adults taking tenofovir disoproxil fumarate.
Adovich S Rivera, Katherine J. Pak, M. Mefford, R. Hechter   +3 more
semanticscholar   +1 more source

Tenofovir vs Entecavir Among Patients With HBV-Related HCC After Resection

JAMA Network Open, 2023
Key Points Question What are the recurrence-free and overall survival rates associated with tenofovir disoproxil vs entecavir among patients with hepatocellular cancer (HCC) related to hepatitis B virus (HBV) after liver resection with curative intent ...
Pengpeng Li, Yuanyuan Wang, Jian Yu, Judian Yu, Qifei Tao, Jinwei Zhang, Wan-Yee Lau, Weiping Zhou, Gang Huang   +8 more
semanticscholar   +1 more source

Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.

New England Journal of Medicine, 2021
BACKGROUND The World Health Organization recommends dolutegravir with two nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human immunodeficiency virus type 1 (HIV-1) infection. Evidence is limited for the efficacy of this
Nicholas I. Paton, J. Musaazi, C. Kityo, S. Walimbwa, A. Hoppe, Apolo Balyegisawa, A. Kaimal, G. Mirembe, Phionah Tukamushabe, Gilbert Ategeka, J. Hakim, H. Mugerwa, A. Siika, Jesca Asienzo, B. Castelnuovo, A. Kiragga, A. Kambugu   +16 more
semanticscholar   +1 more source

Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B: week 144 results from a real‐world, multi‐centre cohort study

Alimentary Pharmacology and Therapeutics, 2022
Tenofovir alafenamide (TAF) may be preferable to other nucleos(t)ide analogues (NA) regarding outcomes against chronic hepatitis B virus (HBV) infection.
E. Ogawa, M. Nakamuta, Toshimasa Koyanagi, Aritsune Ooho, N. Furusyo, E. Kajiwara, K. Dohmen, A. Kawano, T. Satoh, Kazuhiro Takahashi, K. Azuma, Nobuyuki Yamashita, N. Yamashita, R. Sugimoto, H. Amagase, M. Kuniyoshi, Y. Ichiki, C. Morita, Masaki Kato, S. Shimoda, H. Nomura, J. Hayashi   +21 more
semanticscholar   +1 more source

Weight and metabolic changes after switching from tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC+DTG and TDF/FTC/efavirenz (EFV) to TDF/lamivudine (3TC)/DTG.

Clinical Infectious Diseases, 2022
Participants randomised to first-line tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC+DTG or TDF/FTC/efavirenz (EFV) for 192 weeks were then switched to TDF/lamivudine (3TC)/DTG for 52 weeks ...
Bronwyn Bosch, Godspower Akpomiemie, N. Chandiwana, Simiso M Sokhela, Andrew Hill, K. McCann, A. Qavi, Manya Mirchandani, W. Venter   +8 more
semanticscholar   +1 more source

Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B

PLoS ONE, 2022
For long-term treatment of hepatitis B virus (HBV) infection, switching from tenofovir-disoproxil-fumarate (TDF) to tenofovir-alafenamide (TAF) may prevent renal dysfunction and bone loss.
Kazuharu Suzuki, G. Suda, Yoshiya Yamamoto, S. Abiko, K. Kinoshita, S. Miyamoto, R. Sugiura, M. Kimura, Osamu Maehara, Ren Yamada, Takashi Kitagataya, T. Shigesawa, M. Ohara, N. Kawagishi, Masato Nakai, T. Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, N. Sakamoto   +19 more
semanticscholar   +1 more source

Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. [PDF]

, 2007
BackgroundWe reported previously on the emergence and clinical implications of simian immunodeficiency virus (SIVmac251) mutants with a K65R mutation in reverse transcriptase (RT), and the role of CD8+ cell-mediated immune responses in suppressing ...
Bischofberger, Norbert, Blackwood, Emily J, Heneine, Walid, Johnson, Jeffrey A, Lipscomb, Jonathan, Marthas, Marta L, Matthews, Timothy B, North, Thomas W, Pedersen, Niels C, Singh, Raman P, Van Rompay, Koen KA   +10 more
core   +3 more sources

Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients

Medicine, 2016
To assess the safety and efficacy of rilpivirine in combination with emtricitabine and tenofovir (RPV/FTC/TDF) as a once-daily single-tablet regimen (STR) in HIV-1-infected children and adolescents we performed a multicenter case series study of HIV-1 ...
Lola Falcón-Neyra, C. Palladino, M. N. Navarro Gómez, P. Soler-Palacín, M. González-Tomé, S. J. de Ory, M. Frick, C. Fortuny, A. Noguera-Julian, Elena Bermúdez Moreno, J. Santos, P. Olbrich, L. López-Cortés, V. Briz, O. Neth   +14 more
semanticscholar   +1 more source

Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic Hepatitis B virus infected patients [PDF]

, 2012
Natural killer (NK) cells play a critical role in innate antiviral immunity, but little is known about the impact of antiviral therapy on the frequency of NK cell subsets.
Chi, X., Hou, J., Hu, X., Jin, Q., Lv, J., Niu, J., Pan, Y., Sun, H., Tian, Z., Tu, Z., Xiao, W., Xu, D., Yan, H.   +12 more
core   +3 more sources